EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND DACLATASVIR COMBINATION FOR THE TREATMENT OF HEPATITIS C
Article Sidebar
Main Article Content
Abstract
Objective: To determine the effectiveness and safety of sofosbuvir and daclatsvir combination for the treatment of hepatitis C.
Methodology: This study, of 145 patients, was done in the OPDs of Gastroenterology Unit, LRH & HMC of Khyber Pakhtunkhwa, from January 1st 2017 to December 1st, 2017. HCV infected Patients aged more than 18 years, of either gender, irrespective of previous treatment status having normal hematological tests and ultrasound were included.
Results: Ninty three patients (64.13%) were male and 52 (35.86%) female. Mean age was 39.27 ±10.95. Genotype 3 was the most common genotype, present in 130 (89.65%) patients. All patients with HCV Genotype 3, Genotype 2 and Genotype 1 and untypeable had undetectable HCV RNA at week 4, while 122 (93.84%) patients with HCV Genotype 3; 6(85.71%) patients with Genotype 2; and 4(100%) each with Genotype 1 and untypeable had undetectable HCV RNA twelve weeks after treatment completion. Ten (6.89%) patients developed fatigue, 9(6.20%) patients developed nausea while 8(5.51) patients complained of headache.
Conclusion: Combination of sofosbuvir and daclatasvir was found highly effective with high safety profile in HCV infected patients in our set up.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.